Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Pre-Mixed fluid aims to prevent mineral loss during ICU kidney therapy

NCT ID NCT07550894

Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new pre-mixed fluid that contains phosphate for patients in the ICU who need continuous kidney replacement therapy (CRRT). The standard fluid often washes out phosphate, causing muscle weakness and breathing problems. The trial will compare the new fluid to the standard one in 220 adults across 15 hospitals to see if it keeps phosphate levels normal and is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Phosphate-containing replacement fluid
What this could lead to
If it works, this could provide a safer, more consistent way to maintain healthy phosphate levels during kidney replacement therapy in the ICU.
What could go wrong
This is an early-phase trial with only 220 participants, so results may not apply to all patients. The new fluid could cause electrolyte imbalances or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the following criteria to be eligible for the study: 1. Aged 18 years or older, regardless of gender. 2. Meet the clinical indications for Continuous Renal Replacement Therapy (CRRT) as defined by the "Standard Operating Procedures for Blood Purification (2021 Edition)" and assessed by a qualified nephrologist or intensive care physician. 3. Expected continuous blood purification duration is 72 hours or longer. 4. The participant or their legal guardian has a full understanding of the purpose and significance of the trial, voluntarily agrees to participate and comply with the study procedures, and has signed the written Informed Consent Form (ICF). Exclusion Criteria: * Participants meeting any of the following criteria will be excluded from the study: 1. Known allergy to any component of the investigational drug, or individuals with an allergic constitution. 2. Inability to establish suitable vascular access for CRRT. 3. Persistent hypotension (Systolic Blood Pressure \< 90 mmHg or Mean Arterial Pressure \< 65 mmHg) that is difficult to correct, unless judged by the investigator as potentially correctable with intervention. 4. Presence of malignant tumors with systemic metastasis (except for those who previously underwent radical surgery without recurrence). 5. Pregnant or breastfeeding women. 6. Receipt of any form of renal replacement therapy (RRT) or blood purification treatment within 24 hours prior to screening. 7. Receipt of peritoneal dialysis within 24 hours prior to screening. 8. Participation in any other clinical trial involving investigational drugs or devices within 1 month prior to screening. 9. Any other condition or reason that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Critically ill patients requiring continuous renal replacement therapy Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • Renji Hospital, Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Xi 'An Jiaotong University

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The First Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Third Affiliated Hospital, Sun Yat-Sen Unive

    Guangzhou, Guangdong, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Zhujiang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.